Upcoming Conferences for PolyPid to Expand Investor Engagement

PolyPid's Upcoming Conferences
PolyPid Ltd. (NASDAQ: PYPD), a pioneering biopharmaceutical company focused on enhancing surgical outcomes, is preparing to participate in key investor conferences this autumn.
Lytham Partners Fall 2025 Virtual Investor Conference
On September 30, 2025, PolyPid will present at the Lytham Partners Fall 2025 Virtual Investor Conference. This event will spotlight innovative advancements in surgical technology aimed at improving patient outcomes.
Details of the Presentation
The presentation will feature a conversation led by Chase Knickerbocker, Senior Research Analyst at Craig-Hallum, starting at 4:15 p.m. ET. Attendees will have the opportunity to participate in one-on-one virtual meetings with company representatives.
Accessing the Webcast
Investors can follow the conference through the provided web links, ensuring they remain updated on PolyPid's developments and offerings. A replay of the webcast will be available for those unable to attend the live session.
4th Annual ROTH Healthcare Opportunities Conference
Shortly after, on October 9, 2025, PolyPid will engage in one-on-one meetings at the 4th Annual ROTH Healthcare Opportunities Conference held at the Metropolitan Club. This conference provides another platform for the company to connect with investors and share insights into their innovative pipeline.
Networking Opportunities
By participating in both of these significant events, PolyPid is poised to enhance relationships with current and potential investors, fostering discussions around its product development and business strategies.
About PolyPid
PolyPid Ltd. specializes in late-stage biopharmaceuticals, specifically targeting improvements in surgical procedures. The company's cutting-edge PLEX technology allows for localized drug delivery through controlled release mechanisms, with the aim of significantly reducing surgical site infections.
Key Developments Ahead
As PolyPid prepares for the anticipated New Drug Application (NDA) submission of D-PLEX???, their lead product designed to prevent abdominal colorectal surgical site infections, the company continues to explore innovations across its pipeline catering to oncology, obesity, and diabetes treatment.
Connect with PolyPid
For more information, interested parties can visit PolyPid's official website or connect through their social media platforms, including Twitter and LinkedIn.
Frequently Asked Questions
What is PolyPid known for?
PolyPid is a late-stage biopharmaceutical company focused on improving surgical outcomes using advanced drug delivery methods.
When is PolyPid's presentation at the Lytham Partners Conference?
PolyPid will present at the Lytham Partners Fall 2025 Virtual Investor Conference on September 30, 2025.
What technology does PolyPid utilize?
They leverage their proprietary PLEX technology for localized and controlled drug release during surgical procedures.
What are the main products in PolyPid's pipeline?
The company is advancing D-PLEX??? for prevention of surgical site infections and exploring treatments in oncology, obesity, and diabetes.
How can investors reach PolyPid for meetings?
Investors interested in one-on-one meetings can contact PolyPid through the details provided during the conferences.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.